Hydroxyapatite vs fluoride toothpaste

If you are comparing hydroxyapatite (HA) and fluoride toothpaste, start with the inconvenient fact:

Fluoride has a substantially larger and longer evidence base for caries prevention than hydroxyapatite.

A 2019 Cochrane network meta-analysis by Walsh and colleagues included 96 studies and supports fluoride toothpaste over non-fluoride toothpaste for reducing caries, with dose-response patterns across common concentrations. Hydroxyapatite’s modern clinical caries story rests mainly on a handful of randomised non-inferiority trials—mostly industry-funded, much smaller, and designed to show HA is not worse than fluoride within a margin, not that it is better.

This site is operated by Klyyr, which sells fluoride-free HA toothpaste. That ownership makes the above sentence a credibility requirement, not optional hedging. Readers checking whether a brand-owned guide can be trusted should start here.

How to use this page

Read it as a decision aid, not a prescription.

• If you want mechanism detail, stay for the next sections.
• If you want trial numbers, jump to the caries evidence sections.
• If you want a practical choice framework, skip to Who might reasonably choose which.
• If you are comparing fluoride-free pastes in general, also read Does fluoride-free toothpaste actually work?.

Two different tools

Fluoride and hydroxyapatite are not the same active with different branding. They work differently.

For how HA’s remineralisation story is measured in lab and in-situ work, see Does hydroxyapatite remineralise teeth?.

What “non-inferiority” means (and what it does not)

Non-inferiority trials ask whether a new option is not unacceptably worse than a standard, within a pre-agreed margin.

They do not prove superiority. They do not equal “as proven as fluoride.” A common margin in the HA caries trials was about 20%—generous by everyday language standards.

When headlines say “HA worked as well as fluoride,” check whether the study was a non-inferiority design, who funded it, how long it ran, and what endpoint was used.

The fluoride evidence base

Walsh et al., Cochrane Review, 2019:

• 96 studies included.
• High- or moderate-certainty evidence that 1,000–1,250 ppm and 1,450–1,500 ppm fluoride toothpaste reduce caries increments versus non-fluoride toothpaste in permanent dentition comparisons summarised in the review (for example, SMDs around −0.28 and −0.36 versus non-fluoride in network analyses cited in the abstract).
• Follow-up in most studies was measured in years, often around 36 months.
• Decades of public-health use; FDA OTC anticaries monograph recognition; ADA Seal cavity-protection products require fluoride.

That volume and duration are why major US dental guidance still centres fluoride for anticaries toothpaste claims.

What fluoride does on the tooth

In plain language:

1. When enamel loses mineral under acid attack (demineralisation), fluoride present at the surface helps rebuild a more acid-resistant mineral (often described as fluorapatite-like).
2. Fluoride makes it harder for new demineralisation to progress as quickly.
3. At higher local concentrations, fluoride also has antimicrobial effects in plaque.

Fluoride does not grow back a hole that already needs a filling. Neither does HA. Both are about tipping the daily demineralisation–remineralisation balance—especially for early lesions—while cleaning habits and diet do the rest.

Why the evidence asymmetry matters

It is tempting to treat one good HA trial as cancelling fifty older fluoride trials. That is not how evidence hierarchies work for public-health defaults.

Fluoride’s literature includes long follow-ups, many independent groups, multiple concentrations, primary and permanent teeth, and formal systematic synthesis. HA’s modern caries RCTs are important and worth reading carefully. They are still a thin slice by comparison—especially once you note shared manufacturer ecosystems and non-inferiority margins.

The hydroxyapatite caries trials

The modern HA caries case rests especially on three randomised non-inferiority trials. Fuller study-by-study notes live in Hydroxyapatite and cavity prevention.

Schlagenhauf et al., 2019 (orthodontic patients)

• Multicentre, double-blind, non-inferiority; about 6 months; roughly 150 highly caries-susceptible orthodontic patients.
• Test: fluoride-free 10% microcrystalline HA.
• Control: 1,400 ppm fluoride (amine fluoride + stannous fluoride) toothpaste.
• Primary endpoint: new enamel caries ICDAS ≥1 on specified vestibular surfaces after bracket placement.
• Approximate results: ICDAS ≥1 increase in 56.8% (ITT) / 54.7% (PP) HA vs 60.9% (ITT) / 61.6% (PP) fluoride; non-inferiority met.
• Limits: short duration; specialised high-risk cohort; control formula differed beyond fluoride alone; professional cleaning and chlorhexidine gel may have suppressed overall caries challenge.

Paszynska et al., 2021 (children)

• Double-blind RCT; about 1 year (336 days); ITT n=207; PP n=177.
• Test: 10% microcrystalline HA, fluoride-free, three times daily.
• Control: 500 ppm amine fluoride (European children’s strength—not adult 1,000–1,450 ppm).
• Result: ICDAS ≥1 increase 72.7% HA vs 74.2% fluoride; non-inferiority margin met.
• Funding: Dr. Kurt Wolff GmbH & Co. KG (manufacturer of the test product).
• Limits: industry funding; lower-strength fluoride control; high absolute caries incidence in both arms; primary dentition only.

Paszynska et al., 2023 (adults)

• 18-month double-blind non-inferiority RCT; ITT n=189; PP n=171; ages 18–45.
• Test: fluoride-free 10% HA.
• Control: matched toothpaste with 1,450 ppm NaF.
• Primary endpoint: percentage of subjects with no increase in DMFS.
• Results (PP): 89.3% HA vs 87.4% fluoride with no DMFS increase; non-inferiority met.
• Funding / COI: funded by Dr. Kurt Wolff; several co-authors are company employees.
• Limits: industry funding; relatively low caries activity (most subjects had no DMFS increase—limited assay sensitivity for superiority); 18 months shorter than classic multi-year fluoride field trials.

Updated systematic reviews that pool these RCTs generally conclude that clinical non-inferiority evidence is stronger than it was a decade ago—and still based on few trials.

Cross-cutting limitations (apply to almost all HA caries papers)

1. Sample sizes typically hundreds, not thousands.
2. Duration often 6–18 months versus multi-year fluoride field trials.
3. Industry funding concentrated (notably Dr. Kurt Wolff / Karex-line products; historically Sangi for Japanese products).
4. Non-inferiority margins (often ~20%) are generous.
5. Product heterogeneity (micro vs nano vs ZnCHA; % HA; abrasives; co-actives).
6. Positive systematic reviews sometimes share author networks with manufacturers—disclose when summarising.

If an article (including this one) skips those limits, treat it as incomplete.

Remineralisation: where the stories overlap

Lab and in-situ work show both fluoride and HA can support mineral gain in early lesions. Najibfard et al. (2011) found 5% and 10% nano-HA remineralisation comparable to 1,100 ppm fluoride for mineral gain in that in-situ protocol. Amaechi and colleagues have reported non-inferior HAP versus amine fluoride toothpaste outcomes in children’s in-situ remineralisation work.

Overlap in early-lesion mineral metrics is encouraging. It still does not erase the asymmetry in long-duration clinical caries prevention literature. Mechanism similarity is partial: fluoride catalyses acid-resistant repair using salivary ions; HA brings mineral particles and ions directly.

For dentin hypersensitivity, HA has a clearer clinical signal than for “replacing fluoride.”

A 2023 meta-analysis by Limeback, Enax and Meyer (authors Meyer and Enax affiliated with Dr. Kurt Wolff) reported mean relative sensitivity reductions versus placebo of about 39.5%, and versus fluoride of about 23%, across a large set of clinical trials. Mechanism aligns with tubule occlusion.

Earlier work (for example de Melo Alencar et al., 2019) also reported desensitising advantages for nano-HA versus other treatments on some stimuli over short follow-up, while calling for longer trials.

That does not make HA “better than fluoride for cavities.” It does mean someone whose main problem is sensitivity may have a different risk–benefit conversation than someone whose main problem is recurrent decay.

Other outcomes people ask about

• Whitening: HA whitening is surface repair and light scatter, not bleach. Clinical evidence is modest/preliminary compared with peroxide.
• Erosion: Lab and short in-situ work suggest a protective surface layer; long clinical erosion RCTs are limited.
• Gum disease: Do not treat HA as a periodontitis therapy. Standard periodontal care still applies.
• Microbiome: Short in-situ work suggests reduced bacterial adhesion without strong kill; long-term “microbiome balancing” claims overreach.

Keep outcome-specific. A paste can be interesting for sensitivity and still leave fluoride preferred for high caries risk.

Regulation and seals (US)

• Fluoride toothpastes can be marketed as OTC anticaries drugs under FDA Monograph M021 when they use recognised fluoride actives at specified concentrations.
• HA toothpastes sold in the US are generally marketed as cosmetics (cleaning, appearance, comfort). They are not FDA monograph anticaries drugs.
• There is no FDA anti-caries approval for hydroxyapatite toothpaste as a class.
• The ADA Seal of Acceptance for cavity-protection claims requires fluoride. HA pastes generally will not carry that Seal for anticaries.

Educational articles may describe published trials. That is different from labelling a non-fluoride cosmetic paste with drug-style “prevents cavities” claims in US marketing.

Japan recognised a proprietary HA pathway as an anti-caries agent in 1993, after earlier market use. That history explains cultural familiarity; it does not create an ADA Seal or FDA monograph status for HA pastes sold in the United States.

For nano-specific safety opinions in Europe, see Is hydroxyapatite toothpaste safe?.

Fluoride safety without scare tactics

Fluoride toothpaste used as directed is the default public-health recommendation for a reason.

The main practical concern for families is excess ingestion during enamel formation, which can contribute to dental fluorosis. That is why age-based smear/pea-size guidance exists, and why some caregivers look at fluoride-free options for toddlers who swallow paste.

HA avoids contributing to fluoride intake. That is a real differentiator. It is not a licence to imply that recommended-dose fluoride toothpaste is unsafe for typical users.

Acute fluoride toxicity from ordinary toothpaste use is rare when products are used as directed. The public conversation often compresses “fluoride can cause fluorosis if over-ingested in childhood” into “fluoride is poison.” Those are not the same claim. Precision matters—especially on a site that sells fluoride-free paste.

Who might reasonably choose which

This is not medical advice. It is a map of trade-offs.

Reasonable to prefer fluoride when

• You are at high caries risk (frequent new cavities, active lesions, xerostomia, high sugar exposure, limited preventive access).
• You want the largest evidence base and public-health default.
• You want an ADA Seal product for cavity protection.
• Your dentist has specifically recommended a fluoride regimen (including prescription-strength fluoride).
• You are an orthodontic patient without a clear, supervised alternative plan.

For high caries risk, fluoride is the better-evidenced toothpaste active. A promising non-inferiority trial is not a reason to override that without clinical input.

Reasonable to consider hydroxyapatite when

• Dentin hypersensitivity is your primary complaint and you want a mineral-occluding approach.
• A caregiver is managing paste-swallowing in a young child and wants to avoid fluoride intake—while still discussing caries risk with a paediatric dentist (kids guide).
• You prefer a biomimetic / fluoride-free routine after understanding that HA’s caries evidence is smaller, newer, and often industry-funded.
• You live with products and clinicians already familiar with HA’s longer market history (notably Japan).

Reasonable middle paths

• Follow your dentist if they recommend fluoride varnish, prescription fluoride, or a specific paste—even if you use HA at home for comfort goals.
• Do not assume every fluoride-free toothpaste has HA-level clinical data. Many do not.
• Some households keep fluoride paste as the default and use an HA paste when sensitivity flares. That is a practical compromise, not a studied “best of both” protocol.
• Children are a special case: fluorosis risk from swallowed fluoride and caries risk from insufficient prevention both matter. See the kids guide and talk to a paediatric dentist.

Questions worth asking your dentist

1. What is my (or my child’s) caries risk category right now?
2. If I want a fluoride-free HA paste, what warning signs mean we should switch back?
3. Do I need fluoride varnish or prescription fluoride regardless of daily paste?
4. For sensitivity, is an occluding paste enough, or should we check for recession, grinding, or diet acids?

Bring the actual product and its HA percentage if disclosed. Vague “natural toothpaste” conversations are less useful than named actives.

Bottom line

Fluoride remains the best-studied anticaries toothpaste active worldwide. Hydroxyapatite is a chemically coherent, increasingly studied alternative with meaningful sensitivity data and promising—but narrower—caries non-inferiority trials.

Choose based on risk, goals, and clinical advice—not on the idea that HA has “replaced” fluoride in the scientific consensus. It has not.

If you only remember one sentence from this page, make it this: non-inferiority in a few industry-funded trials is encouraging; it is not Cochrane-scale proof, and it is not superiority.